X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is indicated for the treatment of patients with non-small cell lung cancer with MET exon 14 skipping alterations.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
Orpathys (savolitinib), is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
ORPATHYS® (savolitinib), an oral, potent and highly selective MET tyrosine kinase inhibitor, has been included in the updated National Reimbursement Drug List for the treatment of locally advanced or metastatic NSCLC adult patients with MET exon 14-skipping alterations.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Healthcare Security Administration
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 18, 2023
Details:
Preliminary results from SAVANNAH Phase II trial showed that TAGRISSO® (osimertinib) plus savolitinib demonstrated an ORR of 49% in patients with epidermal growth factor receptor-mutated NSCLC with high levels of mesenchymal epithelial transition overexpression.
Lead Product(s): Osimertinib Mesylate,Savolitinib
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
The results from SAVANNAH suggest savolitinib added to Tagrisso (osimertinib) at the time of disease progression could possibly provide these biomarker-selected patients with a potentially less toxic, more effective treatment option.
Lead Product(s): Osimertinib Mesylate,Savolitinib
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hutchmed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
Savolitinib (ORPATHYS), is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors, blocks atypical activation of MET receptor tyrosine kinase pathway.
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
This milestone has been triggered by the initiation of SAFFRON, the first global Phase III study for ORPATHYS in combination with TAGRISSO in EGFR - mutated non-small cell lung cancer patients with mesenchymal epithelial transition receptor driven tumors.
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 06, 2022
Details:
SACHI, a China Phase III study of ORPATHYS® (savolitinib), an oral, potent, and highly selective MET tyrosine kinase inhibitor (“TKI”), in combination with AstraZeneca’s third-generation, irreversible epidermal growth factor receptor (“EGFR”) TKI, TAGRISSO® (osimertinib).
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2021
Details:
The study will evaluate the efficacy and safety of TAGRISSO® in combination with ORPATHYS® comparing to TAGRISSO® alone, a standard-of-care treatment option for these patients.
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
Details:
The Phase II trial is an open-label, two-cohort, multi-center study to evaluate the efficacy, safety and pharmacokinetics (“PK”) of ORPATHYS® in locally advanced or metastatic GC or GEJ patients whose disease progressed after at least one line of standard therapy.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
Details:
ORPATHYS® is an oral, potent, and highly selective MET TK inhibitor that has shown clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations or gene amplification.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration July 13, 2021
Details:
Savolitinib is an oral, potent and selective MET TKI that has demonstrated clinical activity in advanced solid tumors.The approval by the NMPA was based on positive results from a Phase II trial conducted in China in patients with NSCLC with this mutation.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hutchmed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
Savolitinib has been studied in over 1,100 patients to date. In clinical studies, it has shown promising clinical efficacy in patients with MET gene alterations in multiple tumor types with an acceptable safety profile.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Product Name: HMPL-504
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
China MediTech Limited will sell its entire indirect interest in Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), a non-core and non-consolidated OTC drug joint venture business which includes Osimertinib.
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: HMPL-504
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GL Mountrose Investment Two
Deal Size: $169.0 million Upfront Cash: Undisclosed
Deal Type: Divestment March 24, 2021
Details:
final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presented at the upcoming virtual 2020 World Conference on Lung Cancer (WCLC 2020).
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Product Name: HMPL-504
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2021
Details:
New and updated analyses on the ongoing studies of savolitinib, surufatinib, and fruquintinib will be presented at the upcoming ASCO20 Virtual Scientific Program.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
The CALYPSO study is an independently sponsored open-label Phase II study of Imfinzi® in combination with several drug candidates in the treatment of renal cell carcinoma in the U.K. and Spain.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
